EXPEDITED REVIEW
The Cost Effectiveness of Implantable Cardioverter-Defibrillators
Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II
Jack Zwanziger, PhD*,*,
W. Jackson Hall, PhD ,
Andrew W. Dick, PhD*,
Hongwei Zhao, DSc,
Alvin I. Mushlin, MD, ScM*,
Rebecca Marron Hahn, MPH*,
Hongkun Wang, MA,
Mark L. Andrews, BBS ,
Cathleen Mooney, MS*,
Hongyue Wang, MA and
Arthur J. Moss, MD
* Community and Preventive Medicine
Biostatistics and Computational Biology
Cardiology Division of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
Manuscript received December 4, 2005;
revised manuscript received March 2, 2006,
accepted March 16, 2006.
* Reprint requests and correspondence: Dr. Jack Zwanziger, Director, Department of Health Policy and Administration, Center for Health Sciences Research, University of Illinois at Chicago, School of Public Health, Chicago, Illinois 60612-4394 (Email: jzwanzig{at}uic.edu).
OBJECTIVES: We sought to evaluate the cost implications of the implantable cardioverter-defibrillator (ICD), using utilization, cost, and survival data from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
BACKGROUND: This trial showed that prophylactic implantation of a defibrillator reduces the rate of mortality in patients who experienced a previous myocardial infarction and low left ventricular ejection fraction. Given the size of the eligible population, the cost effectiveness of the ICD has substantial implications.
METHODS: Our research comprises the cost-effectiveness component of the randomized controlled trial, MADIT-II, based on utilization, cost, and survival information from 1,095 U.S. patients who were assigned randomly to receive an ICD or conventional medical care. Utilization data were converted to costs using a variety of national and hospital-specific data. The incremental cost-effectiveness ratio (iCER) was calculated as the difference in discounted costs divided by the difference in discounted life expectancy within 3.5 years. Secondary analyses included projections of survival (using three alternative assumptions), corresponding cost assumptions, and the resulting cost-effectiveness ratios until 12 years after randomization.
RESULTS: During the 3.5-year period of the study, the average survival gain for the defibrillator arm was 0.167 years (2 months), the additional costs were $39,200, and the iCER was $235,000 per year-of-life saved. In three alternative projections to 12 years, this ratio ranged from $78,600 to $114,000.
CONCLUSIONS: The estimated cost per life-year saved by the ICD in the MADIT-II study is relatively high at 3.5 years but is projected to be substantially lower over the course of longer time horizons.
|
Abbreviations and Acronyms
| | CONV = conventional therapy | | HR = hazard ratio | | ICD = implantable cardioverter-defibrillator | | iCER = incremental cost effectiveness ratio | | MADIT-II = Second Multicenter Automatic Defibrillator Implantation Trial | | QALY = quality-adjusted life years | | YOLS = years-of-life saved |
|
This article has been cited by other articles:
|
|
|
|
 
T. Chow, D. J. Kereiakes, J. Onufer, A. Woelfel, S. Gursoy, B. J. Peterson, M. L. Brown, W. Pu, D. G. Benditt, and on behalf of the MASTER Trial Investigators
Does Microvolt T-Wave Alternans Testing Predict Ventricular Tachyarrhythmias in Patients With Ischemic Cardiomyopathy and Prophylactic Defibrillators?: The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) Trial
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1607 - 1615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Pellegrini, K. Lee, J. E. Olgin, M. P. Turakhia, Z. H. Tseng, R. Lee, N. Badhwar, B. Lee, and P. D. Varosy
Impact of advanced age on survival in patients with implantable cardioverter defibrillators
Europace,
November 1, 2008;
10(11):
1296 - 1301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tung, P. Zimetbaum, and M. E. Josephson
A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1111 - 1121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein
Benefits of the Implantable Cardioverter-Defibrillator
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1122 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ding, W. Hua, H. Niu, K. Chen, and S. Zhang
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
Europace,
September 1, 2008;
10(9):
1034 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Goldenberg and A. J. Moss
Long QT syndrome.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2291 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
e1 - e62.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. Mark Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2085 - 2105.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation,
May 27, 2008;
117(21):
2820 - 2840.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation,
May 27, 2008;
117(21):
e350 - e408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Bach
Cost Sharing for Health Care -- Whose Skin? Which Game?
N. Engl. J. Med.,
January 24, 2008;
358(4):
411 - 413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Goldenberg, A. K. Vyas, W. J. Hall, A. J. Moss, H. Wang, H. He, W. Zareba, S. McNitt, M. L. Andrews, and for the MADIT-II Investigators
Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction
J. Am. Coll. Cardiol.,
January 22, 2008;
51(3):
288 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sleight
New Methods for Risk Stratification in Patients After Myocardial Infarction: Autonomic Control and Substrate Sensitivity
J. Am. Coll. Cardiol.,
December 11, 2007;
50(24):
2291 - 2293.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Krumholz and F. A. Masoudi
The Year in Epidemiology, Health Services Research, and Outcomes Research
J. Am. Coll. Cardiol.,
December 4, 2007;
50(23):
2254 - 2262.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ezekowitz, B. H. Rowe, D. M. Dryden, N. Hooton, B. Vandermeer, C. Spooner, and F. A. McAlister
Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction
Ann Intern Med,
August 21, 2007;
147(4):
251 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Passman and A. Kadish
Sudden Death Prevention With Implantable Devices
Circulation,
July 31, 2007;
116(5):
561 - 571.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Zimetbaum
A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator
JAMA,
May 2, 2007;
297(17):
1909 - 1916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Heidbuchel
The cost of implantable defibrillators: how the perception of reality depends on perspective
Eur. Heart J.,
February 8, 2007;
(2007)
ehl518v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hlatky and D. B. Mark
The high cost of implantable defibrillators
Eur. Heart J.,
February 2, 2007;
28(4):
388 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. Stevenson
Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Death in Heart Failure: Are There Enough Bangs for the Bucks?
Circulation,
July 11, 2006;
114(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
